SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bio-Techne Corporation - TECH

NEW YORK, Aug. 30, 2017

The investigation concerns whether Bio-Techne and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On August 29, 2017, Bio-Techne announced that the Company would be unable to timely file its Annual Report for the fiscal year ended June 30, 2017, citing the "greater-than-anticipated time, resources and effort required to complete work related to the assessment of the Company's internal control over financial reporting."  Having identified material weaknesses in internal controls at the end of the prior fiscal year, Bio-Techne advised investors that "[t]he Company believes it has made significant progress in changing the design of our controls as of June 30, 2017; however, the Company believes that material weaknesses still remain within some aspects of its internal control framework." 

On this news, Bio-Techne's share price has fallen as much as $1.48, or 1.21%, during intraday trading on August 30, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com